Abstract Library

#4562 Secondary endpoint results of the first multicentric randomised phase II trial investigating the antitumour efficacy of 177Lutetium-DOTA-Octreotate (OCLU) in advanced progressive neuroendocrine pancreatic tumour: The OCLURANDOM trial

Introduction: No published randomised trial investing the role of PRRT (177Lutetium-DOTA-Octreotate) in advanced progressive PaNET patients.

Conference:

Presenting Author: Baudin E

Authors: Baudin E, Walter T, Beron A, Smith D, Deandreis D,

Keywords: Pancreatic neuroendocrine, randomised phase 2 trial, Lutathera, Sunitinib,

#4096 Co-production of patient information: A model for today’s practice

Introduction: According to the British Medical Association, good quality patient information is fundamental to effective, patient-centred, quality care. It rightly considers patients as partners in their care, “Co-production involves engaging groups of people who use healthcare services, in equal partnership; at the earliest stages of service design, development and evaluation. It acknowledges that people with ‘lived experience’ of a particular condition are often best placed to advise on what support and services will make a positive difference to their lives.” (NHS England) The re-introduction of a liver transplantation programme in the UK for selected patients with a Neuroendocrine Neoplasm offers new opportunities to improve survival and quality of life: good quality information is a key tool for informed consent.

Conference:

Presenting Author:

Authors: Jervis N, Ellis C, Smith S, Shah T, Lewis K,

Keywords: Liver Transplantation, Co-production, Patient Information, Lived Experience Contribution,

#3575 Claudin 18 immunohistochemistry for determining site of origin of metastatic neuroendocrine tumor

Introduction: Claudin 18 isoform 2 (CLDN18.2) is selectively expressed in normal and neoplastic gastric tissue and some pancreatic neoplasia. Anti-CLDN18.2 is an investigational therapy in gastric and pancreatic adenocarcinoma and a sensitive and specific immunohistochemical marker in these cancers.

Conference:

Presenting Author: Smith B

Authors: Smith B, Rice K, Setthavongsack N, Woltjer R, Wong M,

Keywords: neuroendocrine, immunohistochemistry, claudin 18, CLDN18, gastric,

#3542 Essential role of nutritional support in patients with advanced carcinoid heart disease

Introduction: Chronic heart failure leads to cachexia in 5-15% of patients. Malnutrition affects 58% of patients with carcinoid syndrome.

Conference:

Presenting Author:

Authors: Shah H, Mair R, Arif S, Smith S, Vickrage S,

Keywords: carcinoid syndrome, carcinoid heart disease, nutrition, nasogastric feeding,

#3517 The role of the NET clinical nurse specialist in managing carcinoid heart disease patients: Optimising patient care

Introduction: The diagnosis of carcinoid heart disease (CHD) is often made late and requires a highly experienced team to manage multiple issues, such as heart failure, carcinoid symptoms and poor nutrition. Prior to December 2018 NET (Neuroendocrine Tumor) and cardiac teams were working in isolation, this resulted in missed opportunities for intervention and comprehensive review. It was evident we needed to build closer collaborations with our cardiac colleagues, to ensure timely assessment, optimisation of symptoms and improve patients’ overall experience. The Clinical Nurse Specialists (CNSs) were fundamental in establishing a twice monthly CHD/NET multidisciplinary team meeting and monthly joint NET/CHD clinic. Patients were kept informed at each stage by the CNS, either during telephone consultation, ward visit or at clinic appointments.

Conference:

Presenting Author:

Authors: Smith S, Vickrage S, Kemp-Blake J, Coldham C, Shah T,

Keywords: Carcinoid Heart Disease, Multidisciplinary team, Clinical Nurse Specialist,